The histological and molecular features and even the mere existence of diffuse astrocytoma, IDH-wildtype, remain unclear. We therefore examined 212 diffuse astrocytomas (grade II WHO) in adults using IDH1(R132H) immunohistochemistry followed by IDH1/IDH2 sequencing and neuroimaging review. DNA methylation status and copy number profiles were assessed by Infinium HumanMethylation450k BeadChip. Only 25/212 patients harbored tumors without IDH1/IDH2 hotspot mutations and without contrast enhancement. By DNA methylation profiling, 10/25 tumors were classified as glioblastoma, IDH-wildtype, and an additional 7 cases could not be classified using methylome analysis, but showed genetic characteristics of glioblastoma. Histologically, all of these 17 tumors were low-grade diffuse astrocytomas. Nevertheless, 10/17 patients experienced early malignant progression. Other methylation classes included diffuse midline glioma, H3 K27M-mutant, diffuse astrocytoma, IDH-mutant, pilocytic astrocytoma, and normal or reactive brain tissue (total n ¼ 8). In conclusion, no convincing diffuse astrocytoma, IDH-wildtype, was identified. Most IDH-wildtype tumors showing histopathological and radiological features of low-grade diffuse astrocytoma exhibit molecular and clinical features of high-grade glioma and may represent an early stage of primary glioblastoma. Our findings have implications for the biology, classification and neuropathological diagnosis of diffuse astrocytoma, IDH-wildtype in adults.
INTRODUCTION
Diffuse astrocytomas are common brain tumors mainly affecting young adults (1, 2) . The majority of adult diffuse astrocytomas carry IDH1 (R132) or IDH2 (R172) hotspot mutations, resulting in an integrated diagnosis of "diffuse astrocytoma, IDH-mutant" according to WHO criteria (3) . In the absence of IDH1/IDH2 mutations, diffuse astrocytic tumors can be diagnosed as "diffuse astrocytoma, IDHwildtype", but clinical and molecular features remain unclear and even the mere existence of diffuse astrocytoma, IDHwildtype, has been questioned (4) . In a previous series of 160 IDH-wildtype diffuse astrocytic tumors (grades II and III) of adults, molecular analyses resolved the vast majority of cases into other tumor entities and 78% of tumors showed clinical features as well as genetic alterations and/or epigenetic profiles characteristic of glioblastoma (4) . Because the majority of these tumors comprised anaplastic astrocytomas and neuroimaging was not considered, one could argue that sampling bias and intratumoral heterogeneity (5) could have been involved in the underdiagnosis of glioblastoma, IDH-wildtype as "astrocytoma, IDH-wildtype" in this series. We therefore aimed to explore the clinical, histopathological and molecular features of diffuse astrocytoma, IDH-wildtype from a series of 215 consecutive diffuse astrocytomas (grade II WHO) of adult patients, which were carefully characterized using IDH1 (R132) immunohistochemistry followed by IDH1/IDH2 sequencing and neuroimaging review.
MATERIALS AND METHODS

Patient Samples
Formalin-fixed paraffin-embedded tumor samples of 212 consecutive open biopsies or resections of diffuse astrocytomas (grade II WHO) operated at 3 neurosurgical departments (University Hospital Münster, Clemenshospital Münster, St. Barbara-Klinik Hamm) throughout a 6-year period (2011-2016) were retrieved from our tumor bank and examined retrospectively. Reports of preoperative magnetic resonance imaging studies were reviewed by a neuroradiologist for the presence or absence of contrast enhancement. Data on progression-free survival were compiled by reviewing patient records. The tumor bank received local ethical committee approval (Ethics committee of the University Hospital Münster).
Histopathology
Tumors were reviewed according to current WHO criteria (3). The routine diagnostic work-up included immunohistochemistry for GFAP, mutated IDH1(R132) protein (6), p53, ATRX, and Ki67/MIB1 using standard protocols on an automated staining system (DAKO, Glostrup, Denmark).
IDH Sequencing
After isolation of genomic DNA from formalin-fixed paraffin-embedded tumor samples using the Maxwell Purification Kit (Promega, Madison, WI), Sanger sequencing for IDH1 and IDH2 hotspot mutations was performed using primers and protocols as described previously (7).
DNA Methylation Profiling
After DNA isolation from formalin-fixed paraffinembedded tumor samples using the Maxwell Purification Kit (Promega), purification and bisulfite conversion using standard protocols provided by the manufacturer (Illumina, Inc., San Diego, CA), all samples were analyzed using the HumanMethylation450 BeadChip array (Illumina, Inc.). Resulting DNA methylation profiles were analyzed using the MNP classifier score (version 11b2). The classifier algorithm allows for comparison with over 2.800 cases of a reference cohort and is based on the random forest algorithm (https://www.molecularneuropathology. org/mnp, last accessed February 2, 2018). Copy number variation analysis from methylation array data was performed using the conumee Bioconductor package (http://bioconductor.org/ packages/release/bioc/html/conumee.html, last accessed February 2, 2018) and copy number profiles were examined by manual inspection.
Next-Generation Sequencing
Next-generation sequencing was performed using a customized enrichment/hybrid-capture-based panel comprising the entire coding and selected intronic and promoter regions of 130 genes recurrently altered in brain tumors, allowing for the detection of single nucleotide variations, fusions, and copy number aberrations as described previously (8) .
RESULTS
The median age of the 212 patients was 44 years (interquartile range: 35-52 years, range: 18-81 years). Histopathologically, all tumors were low-grade diffuse astrocytomas. As summarized in Figure 1 , 87 tumors were immunonegative for IDH1(R132H). From the review of preoperative imaging studies, only 44 of these tumors lacked contrast enhancement. Cases showing contrast enhancement were regarded as likely representing anaplastic astrocytoma or glioblastoma and were discarded from further analysis. Subsequent IDH1/IDH2 sequencing identified a further 16 of these tumors as having IDH1 mutations, and 3 with IDH2 mutations, leaving only 25 IDH-wildtype tumors (representing 12% of all 212 low-grade diffuse astrocytomas), which were then subjected to further molecular analyses.
DNA methylation profiling demonstrated that 10 of these 25 tumors had epigenetic abnormalities typical of glioblastoma, IDH-wildtype (Supplementary Data Table S1 ). An additional 7 cases could not be so classified using DNA methylation profiling, but showed copy number alterations also characteristic of glioblastoma (gains of chromosome 7 and losses of chromosome 10). Furthermore, next-generation sequencing for 130 genes recurrently altered in brain tumors performed in these cases revealed mutations frequently encountered in glioblastomas (e.g. TERT (9), PIK3CA, and MSH6); for details see Supplementary Data Table S1 . Histologically, all of these 17 tumors were low-grade diffuse astrocytomas of low to moderate cellularity and no significant mitotic activity. The mean Ki67/MIB1 proliferation index was 4% (range: 1%-15%). Of note, these 17 patients were significantly older than the whole group (median age 57 years, MannWhitney-U-Test p < 0.001). After a median follow up of 10 months, 10 of these 17 patients experienced malignant progression and a diagnosis of anaplastic astrocytoma or glioblastoma, IDH-wildtype, was established on histopathological examination of a biopsy of the recurrence. Other methylation classes included diffuse midline glioma, H3 K27M-mutant (2 cases, located in the corpus callosum and pons, respectively), pilocytic astrocytoma (n ¼ 1, not showing characteristic features of pilocytic astrocytoma on histopathological review), diffuse astrocytoma, IDH-mutant (n ¼ 1, case not harboring an IDH1/ IDH2 hotspot mutation, raising the possibility of a rare nonhotspot IDH mutation), and normal brain tissue (n ¼ 1, sample available for analysis lacked tumor present in the original diagnostic specimen). Three methylome-unclassifiable cases without copy number profile alterations showed relatively few invading glioma cells, highlighting the limitations of molecular pathology techniques for infiltrating gliomas, which are histopathologically recognizable, but in which molecular abnormalities are not detectable among a majority of normal or reactive cells.
DISCUSSION
The 17 IDH-wildtype tumors identified in the present series showed histopathological and radiological features of lowgrade gliomas, but exhibited molecular and in the majority also clinical features of high-grade glioma with rapid recurrence as anaplastic astrocytoma or glioblastoma. These findings have implications for the biology, classification and neuropathological diagnosis of diffuse astrocytoma, IDH-wildtype.
Biologically, these tumors probably represent an early stage of primary glioblastoma. Even though there were no histopathological signs of high-grade nature in these tumors, the tumor cells already show genetic and/or epigenetic features of glioblastoma. These findings suggest that development of primary glioblastomas may include early stages that histologically correspond to low-grade tumors. Events involved in the transition from such early tumor stage to full-blown glioblastoma showing increased mitotic activity, vascular proliferates and tumor necrosis remain uncertain, but further research on such cases is expected to shed light on pathways involved in the evolution of primary glioblastoma. Even though samples were from open biopsies or resections and tumors did not show contrast enhancement on preoperative studies, the possibility of sampling bias cannot entirely be excluded. With regards to classification, none of the astrocytomas in the adult patients of the present series showed histopathological, genetic, epigenetic and clinical features consistent with an IDHwildtype WHO grade II tumor. Thus, our study provides no evidence for the existence of diffuse astrocytoma, IDH-wildtype as a distinct entity in adults. These findings extend previous observations (4), but do not entirely exclude the possibility of extremely rare diffuse astrocytomas, IDH-wildtype, in adult patients. In children the situation is different, since pediatric IDH-wildtype diffuse astrocytomas frequently show other genetic alterations involving BRAF, RAF1, FGFR1, MYB, and MYBL1 (10), which are only rarely encountered in adults.
Our findings also have consequences for routine diagnostic neuropathology, because they strongly suggest that in diffuse astrocytic IDH-wildtype tumors further molecular testing (e.g. panel sequencing and/or DNA methylation profiling) in order to identify molecular hallmarks of glioblastoma is to be recommended. Another recent study also highlighted the prognostic role of molecular alterations (i.e. TERT promoter mutation and chromosome 7 and 10 copy number status) in adult diffuse low-grade IDH-wildtype glioma (11) . In addition, molecular testing may also aid in the identification of other tumor entities not showing IDH mutations such as diffuse midline glioma, H3 K27M-mutant, which have to be considered in the differential diagnosis.
In conclusion, no convincing diffuse astrocytoma, IDHwildtype, was identified. Most IDH-wildtype tumors showing histopathological and radiological features of low-grade diffuse astrocytoma exhibit molecular and clinical features of high-grade glioma and may represent an early stage of primary glioblastoma.
